Explore Triple Negative Breast Cancer Diagnosis and Testing

Triple negative breast cancer is diagnosed by examining breast tissue and determining whether cancer cells contain certain hormone receptors or HER2 proteins. The diagnostic process may begin after a person notices a breast change, such as a lump or skin change, or when an abnormality appears during routine breast screening. Healthcare professionals use several tests to identify cancer, confirm its subtype, and understand important characteristics of the tumor.

Understanding the Initial Diagnosis and Imaging Tests

The first stage of diagnosis often involves a clinical evaluation and imaging. A healthcare professional may review symptoms, medical history, and family history before examining the breast and nearby lymph nodes. If an unusual area is identified, imaging tests can provide additional information about its size, location, and appearance.

• Mammography: A mammogram uses low dose X rays to identify unusual areas in breast tissue. It may detect changes that cannot be felt during a physical examination.
• Breast ultrasound: Ultrasound uses sound waves to create images of breast tissue. It can help healthcare professionals examine whether an abnormal area is solid or filled with fluid.
• Magnetic resonance imaging: Breast MRI may be used in selected situations to obtain detailed images and evaluate the extent of an abnormality.
• Clinical breast examination: A physical examination may help identify lumps, changes in breast shape, skin changes, or enlarged lymph nodes.

Imaging tests alone generally cannot confirm whether an abnormality is cancer. When findings require further evaluation, a biopsy is usually performed. During a biopsy, a sample of tissue or cells is removed and examined in a laboratory. Different biopsy techniques may be used depending on the location and characteristics of the area being investigated.

Biopsy and Receptor Testing for Triple Negative Breast Cancer

A biopsy is an important step in confirming breast cancer. A pathologist examines the tissue sample under a microscope to determine whether cancer cells are present. Additional laboratory testing is then performed to identify the biological features of the cancer.

Triple negative breast cancer is identified when testing shows that the cancer cells are negative for estrogen receptors, negative for progesterone receptors, and do not show HER2 positivity. These results are important because receptor status can influence how the cancer is classified and which treatment approaches may be considered.

• Estrogen receptor testing: This test determines whether estrogen receptors are present on the cancer cells.
• Progesterone receptor testing: Laboratory analysis checks whether the cancer cells contain progesterone receptors.
• HER2 testing: HER2 status may be evaluated using laboratory methods that examine the amount of HER2 protein or related genetic changes in the cancer cells.
• Pathology evaluation: The pathology report may also include information about tumor type, grade, and other characteristics observed in the tissue.
• Additional testing: Depending on individual circumstances, healthcare professionals may recommend genetic testing, further imaging, or other assessments to gather more information about the cancer.

Accurate diagnosis of triple negative breast cancer depends on combining imaging findings, biopsy results, pathology analysis, and receptor testing. These assessments help healthcare professionals identify the cancer subtype and understand its characteristics. Because every person and diagnosis is different, test results should be discussed with qualified healthcare professionals who can explain their meaning and outline appropriate next steps based on the individual situation.